+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09400(INAVA Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

INAVA (Immune Nuclear Acidic Vigilante Actuator) is a protein encoded by the *SLC15A4* gene, initially identified for its role in immune regulation and inflammatory responses. It functions as a cytoplasmic scaffold protein involved in innate immune signaling pathways, particularly those mediated by Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors. INAVA facilitates the assembly of signaling complexes that activate NF-κB and mitogen-activated protein kinase (MAPK) pathways, driving pro-inflammatory cytokine production.

Research has linked INAVA dysregulation to autoimmune and inflammatory diseases. Notably, genome-wide association studies (GWAS) highlighted *SLC15A4* polymorphisms as risk factors for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. INAVA's interaction with autophagy-related proteins further suggests its role in maintaining immune homeostasis by modulating pathogen clearance and inflammatory resolution.

INAVA antibodies are essential tools for studying its expression, localization, and function in immune cells. They enable detection via Western blot, immunohistochemistry, and flow cytometry, aiding investigations into INAVA's mechanistic contributions to disease. Therapeutic targeting of INAVA or its pathways is being explored to develop treatments for chronic inflammation and autoimmune disorders, underscoring its biomedical relevance.